AU · rank #9 · 2026-07-27
GH
NASDAQ · $20.67B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.684 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.10 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $78,456 across 1 unique buyers. | 3.000 |
| Analyst upside Consensus target $171.08 | +16.1% |
| Momentum acceleration 3-month minus 12-month momentum. | +19.40% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.70 |
| Gross margin TTM | +64.9% |
| 52w high | $174.08 |
| Market cap (USD) | $20.67B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Guardant Health develops liquid biopsy cancer diagnostics, led by Guardant360, Shield colorectal screening, and biopharma/data services, with Q1 2026 revenue up about 48% y/y and screening scaling rapidly.
Rationale
The setup fits an analyst-upside trade because Street sentiment is clearly improving—10 target raises in 30 days, positive EPS revisions, a 16% target upside, and a strong rating profile—while Q1 beat/re-raise and margin expansion confirm operational traction.
Material risks
- 1Shield adoption still depends heavily on reimbursement and possible ACS guideline inclusion, so any delay or adverse payer decision could slow the main growth vector and undercut the upside case.
- 2Competition in liquid biopsy and blood-based screening remains intense, with large health systems and oncology players able to build or substitute capabilities over time, which could pressure pricing and growth.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.